Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neoadjuvant hormonal deprivation before radical prostatectomy

C C Schulman1, A M Sassine

  • 1Department of Urology, University Clinics of Brussels, Erasme Hospital, Belgium.

Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|December 1, 1993
PubMed
Summary

Neoadjuvant combination therapy, including luteinizing hormone-releasing hormone (LHRH) superagonist and flutamide, significantly reduces prostate cancer volume and improves surgical outcomes before radical prostatectomy. This approach leads to downstaging and fewer positive surgical margins, enhancing patient prognosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erectile dysfunction and cardiovascular diseases.

Archivos espanoles de urologia·2010
Same author

To the German Society of Urology - centennial celebration.

Der Urologe. Ausg. A·2006
Same author

A simple maneuver to replace dislodged laparoscopic port.

Urology·2004
Same author

Handling and reporting of biopsy and surgical specimens of testicular cancer.

European urology·2004
Same author

[Laparoscopy in urology].

Revue medicale de Bruxelles·2003
Same author

Early prostate cancer: prevention, treatment modalities, and quality of life issues.

European urology·2003

Area of Science:

  • Urology
  • Oncology
  • Surgical Oncology

Background:

  • Neoadjuvant hormonal therapy is increasingly used before radical prostatectomy.
  • Its primary goals include downstaging, downgrading, and improving surgical outcomes.

Purpose of the Study:

  • To evaluate the efficacy of neoadjuvant combination therapy (LHRH superagonist and flutamide) in patients undergoing radical prostatectomy.
  • To assess its impact on prostate volume, clinical staging, surgical results, and histopathological outcomes.

Main Methods:

  • Retrospective analysis of 100 radical prostatectomy patients.
  • 40 patients received neoadjuvant combination androgen blockade prior to surgery.
  • Data collected on prostate volume, clinical stage, operative parameters, PSA levels, and surgical margins.

Related Experiment Videos

Main Results:

  • Prostate volume decreased by 40-50% with combination therapy.
  • Clinical downstaging occurred in one-third of treated patients.
  • Positive surgical margins were reduced from 57% in controls to 32% in treated patients.
  • Serum PSA became undetectable in 59% of treated patients.
  • Histological changes noted in neoplastic and non-neoplastic prostatic tissue.

Conclusions:

  • Neoadjuvant combination therapy effectively reduces prostate cancer volume and facilitates radical prostatectomy.
  • This treatment strategy improves surgical outcomes, including reduced positive margins and faster return of continence.
  • Hormonal suppression before surgery shows promising results for downstaging and potentially improving survival in prostate cancer patients.